TFX Stock Analysis: Teleflex | NYSE
Medical Instruments & Supplies | NYSE, USA | Market Cap: 5.934m USD | 12M Return: 14.5% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 57.3M
EPS Trend: -45.7%
Qual. Beats: 0
Rev. Trend: 10.1%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Teleflex Incorporated (NYSE: TFX) is a U.S.-headquartered medical device company that designs, manufactures, and supplies single-use medical devices used in critical care and surgical procedures. Founded in 1943 and based in Wayne, Pennsylvania, the company operates globally across the United States, Europe, the Middle East, Africa, and the Asia Pacific.
The business is organized around three main product platforms. The vascular and emergency medicine segment offers Arrow-branded catheters, navigation and tip positioning systems, intraosseous vascular access systems (including the EZ-IO and Arrow FAST1 lines), and QuikClot hemostatic products. The interventional segment provides coronary catheters, structural heart support devices, peripheral intervention platforms, GuideLiner/Turnpike/TrapLiner catheters, MANTA vascular closure devices, and Arrow OnControl powered bone biopsy systems. The surgical segment supplies ligation clips, fascial closure systems, percutaneous surgical systems, bariatric staplers, and related instruments marketed under brands such as Weck, MiniLap, Pleur-Evac, Deknatel, KMedic, Pilling, and Titan SGS.
Teleflex sells primarily to hospitals, healthcare providers, and medical device manufacturers, and also distributes products through online channels. Within the broader healthcare equipment industry, the companys emphasis on single-use, disposable devices positions it in the medical consumables segment, a business model typically characterized by recurring, procedure-driven demand tied to hospital utilization rather than large capital equipment purchase cycles.
- EZ-IO and Arrow catheter demand fuels vascular access growth
- Surgical segment softens on elective procedure volume declines
- FX and inflation pressures weigh on operating margin outlook
| Net Income: -1.01b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA -3.03 > 1.0 |
| NWC/Revenue: 40.25% < 20% (prev 28.67%; Δ 11.58% < -1%) |
| CFO/TA 0.05 > 3% & CFO 314.2m > Net Income -1.01b |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 2.55 > 1.5 & < 3 |
| Outstanding Shares: last quarter (44.3m) vs 12m ago -3.63% < -2% |
| Gross Margin: 53.27% > 18% (prev 55.68%; Δ -2.40% > 0.5%) |
| Asset Turnover: 40.31% > 50% (prev 42.02%; Δ -1.71% > 0%) |
| Interest Coverage Ratio: -1.97 > 6 (EBIT TTM -222.9m / Interest Expense TTM 113.2m) |
| A: 0.17 (Total Current Assets 1.86b - Total Current Liabilities 728.0m) / Total Assets 6.78b |
| B: 0.46 (Retained Earnings 3.13b / Total Assets 6.78b) |
| C: -0.03 (EBIT TTM -222.9m / Avg Total Assets 6.97b) |
| D: 0.83 (Book Value of Equity 3.08b / Total Liabilities 3.70b) |
| Altman-Z'' = 3.26 = A |
| DSRI: 0.84 (Receivables 365.5m/464.5m, Revenue 2.81b/3.01b) |
| GMI: 1.05 (GM 55.68% / 53.27%) |
| AQI: 0.92 (AQ_t 0.64 / AQ_t-1 0.70) |
| SGI: 0.93 (Revenue 2.81b / 3.01b) |
| TATA: -0.20 (NI -1.01b - CFO 314.2m) / TA 6.78b) |
| Beneish M = -3.23 (Cap -4..+1) = AA |
As of July 11, 2026, the stock is trading at USD 135.73 with a total of 345,014 shares traded. Over the past week, the price has changed by +1.30%, over one month by +2.71%, over three months by +14.94% and over the past year by +14.46%.
Current recommended Stop Loss: 130.90 (which is 3.6% or 1.2 ATR below the current price).
Teleflex has received a consensus analysts rating of 3.07. Therefore, it is recommended to hold TFX.
- StrongBuy: 0
- Buy: 2
- Hold: 11
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 147.2 | 8.5% |
P/E Trailing = 1914.857
P/E Forward = 19.7628
P/S = 2.7902
P/B = 1.8709
P/EG = 0.1641
Revenue TTM = 2.81b USD
EBIT TTM = -222.9m USD
EBITDA TTM = -88.5m USD
Long Term Debt = 2.51b USD (from longTermDebt, last quarter)
Short Term Debt = 103.1m USD (from shortTermDebt, last quarter)
Debt = 2.75b USD (from shortLongTermDebtTotal, last quarter) + Leases 68.3m
Net Debt = 2.44b USD (calculated: Debt 2.75b - CCE 309.4m)
Enterprise Value = 8.38b USD (5.93b + Debt 2.75b - CCE 309.4m)
Interest Coverage Ratio = -1.97 (Ebit TTM -222.9m / Interest Expense TTM 113.2m)
EV/FCF = 33.65x (Enterprise Value 8.38b / FCF TTM 249.0m)
FCF Yield = 2.97% (FCF TTM 249.0m / Enterprise Value 8.38b)
FCF Margin = 8.86% (FCF TTM 249.0m / Revenue TTM 2.81b)
Net Margin = -35.89% (Net Income TTM -1.01b / Revenue TTM 2.81b)
Gross Margin = 53.27% ((Revenue TTM 2.81b - Cost of Revenue TTM 1.31b) / Revenue TTM)
Gross Margin QoQ = 56.07% (prev 54.03%)
Tobins Q-Ratio = 1.24 (Enterprise Value 8.38b / Total Assets 6.78b)
Interest Expense / Debt = 4.11% (Interest Expense 113.2m / Debt 2.75b)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -176.1m (EBIT -222.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.55 (Total Current Assets 1.86b / Total Current Liabilities 728.0m)
Debt / Equity = 0.89 (Debt 2.75b / totalStockholderEquity, last quarter 3.08b)
Debt / EBITDA = -27.63 (negative EBITDA) (Net Debt 2.44b / EBITDA -88.5m)
Debt / FCF = 9.82 (Net Debt 2.44b / FCF TTM 249.0m)
Total Stockholder Equity = 3.57b (last 4 quarters mean from totalStockholderEquity)
RoA = -14.47% (Net Income -1.01b / Total Assets 6.78b)
RoE = -28.27% (Net Income TTM -1.01b / Total Stockholder Equity 3.57b)
RoCE = -3.66% (EBIT -222.9m / Capital Employed (Equity 3.57b + L.T.Debt 2.51b))
RoIC = -2.93% (negative operating profit) (NOPAT -176.1m / Invested Capital 6.02b)
WACC = 6.50% (E(5.93b)/V(8.69b) * Re(8.01%) + D(2.75b)/V(8.69b) * Rd(4.11%) * (1-Tc(0.21)))
Discount Rate = 8.01% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -76.41 | Cagr: -2.91%
[DCF] Terminal Value 73.10% ; FCFF base≈341.3m ; Y1≈299.3m ; Y5≈241.9m
[DCF] Fair Price = 32.47 (EV 3.88b - Net Debt 2.44b = Equity 1.44b / Shares 44.3m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: -45.70 | EPS CAGR: -3.87% | SUE: 0.26 | # QB: 0
Revenue Correlation: 10.09 | Revenue CAGR: 0.34% | SUE: 0.02 | # QB: 0
EPS current Quarter (2026-06-30): EPS=1.27 | Chg30d=+0.15% | Revisions=-40% | Analysts=12
EPS next Quarter (2026-09-30): EPS=1.82 | Chg30d=-0.45% | Revisions=+0% | Analysts=12
EPS current Year (2026-12-31): EPS=6.68 | Chg30d=-0.29% | Revisions=+25% | GrowthEPS=-4.2% | GrowthRev=+15.3%
EPS next Year (2027-12-31): EPS=10.58 | Chg30d=+0.33% | Revisions=+25% | GrowthEPS=+58.3% | GrowthRev=+4.9%
[Analyst] Revisions Ratio: +0% (up=3, down=3)